Stock Analysis on Net
Stock Analysis on Net

Pfizer Inc. (NYSE:PFE)

$24.99

Common-Size Income Statement

Paying user area

Try for free

Pfizer Inc. pages available for free this week:

The data is hidden behind: . Unhide it.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Pfizer Inc., common-size consolidated income statement

Microsoft Excel
12 months ended: Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Product revenues
Alliance revenues
Revenues
Cost of sales
Gross profit
Selling, informational and administrative expenses
Research and development expenses
Acquired in-process research and development expenses
Amortization of intangible assets
Restructuring charges and certain acquisition-related costs
Operating income
Gain on completion of Consumer Healthcare JV transaction
Interest income
Interest expense
Net interest expense
Royalty-related income
Net gains (losses) on asset disposals
Net gains (losses) recognized during the period on equity securities
Income from collaborations, out-licensing arrangements and sales of compound/product rights
Net periodic benefit credits (costs) other than service costs
Certain legal matters, net
Certain asset impairments
Business and legal entity alignment costs
Net losses on early retirement of debt
Haleon/Consumer Healthcare JV equity method income
Other, net
Other income (deductions), net
Income from continuing operations before provision for taxes on income
(Provision) benefit for taxes on income
Income from continuing operations
Discontinued operations, net of tax
Net income before allocation to noncontrolling interests
Net income attributable to noncontrolling interests
Net income attributable to Pfizer Inc.
Preferred stock dividends, net of tax
Net income attributable to Pfizer Inc. common shareholders

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Income statement item Description The company
Operating income The net result for the period of deducting operating expenses from operating revenues. Pfizer Inc. operating income as a percentage of revenues increased from 2021 to 2022 but then decreased significantly from 2022 to 2023.
Income from continuing operations before provision for taxes on income Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Pfizer Inc. income from continuing operations before provision for taxes on income as a percentage of revenues increased from 2021 to 2022 but then decreased significantly from 2022 to 2023.
Net income attributable to Pfizer Inc. The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Pfizer Inc. net income attributable to Pfizer Inc. as a percentage of revenues increased from 2021 to 2022 but then decreased significantly from 2022 to 2023.